MNG Announces New Chief Executive Officer
ATLANTA, GEORGIA – February 1, 2016 – HealthEdge Investment Partners, LLC (“HealthEdge”) is pleased to announce the appointment of Terry Conrad as Chief Executive Officer of Medical Neurogenetics, LLC (“MNG”), a leading provider of molecular and metabolic genetic testing and consultation for various constitutional disorders affecting children and adults.
Mr. Conrad is currently an Operating Partner with HealthEdge, having also served as Chief Executive Officer of Santus, a skincare products business owned and controlled by HealthEdge of which Mr. Conrad continues to serve as a Member of the Board of Managers. Prior to joining MNG, Mr. Conrad was a member of the Board of Directors of HealthEdge’s Fund I portfolio company Advanced Bio-Technologies, which was sold to UK-based Sinclair Pharmaceuticals in 2011.
Mr. Conrad is a 29 year seasoned executive with a track record of improving shareholder value by making companies more efficient, productive, profitable, and global. Mr. Conrad was most recently the President of the US subsidiary for Photocure, a Norwegian based specialty pharmaceutical firm focused on photodynamic therapies in dermatology and cancer diagnositcs. Prior to that, Mr. Conrad was the President and CEO of Merz Pharmaceuticals’ U.S. division, where he and his team grew annual sales from $20.0 million to $75.0 million through organic growth. Prior to his success at Merz, Mr. Conrad held roles in commercial, business and product development at several large pharmaceutical companies including Parke-Davis, Bayer AG and Lederle Laboratories.
HealthEdge Managing Partner Brian Anderson said, “On behalf of the MNG Board and management team, we are thrilled with the appointment of Terry as the Company’s senior executive. He is an experienced leader and operator, and his skill set is uniquely suited to the opportunities and challenges at MNG.”
About Medical Neurogenetics
Medical Neurogenetics is a leading provider of molecular and metabolic genetic testing and consultation for various inherited disorders affecting children and adults. Medical Neurogenetics provides sophisticated neurological, mitochondrial, and cardiac disorders laboratory testing, focusing on testing for epilepsy, muscular dystrophy, and cellular energetics defects, among others. For more information on Medical Neurogenetics, please visit www.mnglabs.com.
HealthEdge Investment Partners, LLC is an operating-oriented private equity firm founded in 2005 that focuses exclusively on the healthcare industry. HealthEdge seeks to achieve superior returns by investing in businesses that benefit from the knowledge, experience, and network of relationships of its partners. HealthEdge’s partners have more than 100 years of combined operating experience in healthcare as CEOs and investors. For more information on HealthEdge, please visit www.healthedgepartners.com.
For more information, please contact Brian Anderson at HealthEdge Investment Partners at (813) 490-7102.